“In 132 patients with Parkinson’s disease dementia, the drug significantly improved cognitive function and memory as well as REM sleep. This includes complex cognitive tasks that impact quality of life such as making a choice between similar objects and remembering daily personal experiences, which could be impaired in Parkinson’s disease. In patients with Alzheimer’s disease a Phase 2a trial demonstrated a concentration dependent response in both cognition (MMSE) and function (ADCS-ADL) over 148 weeks (longer than 3 years).”
Is there a way to see how this test is going? When it concludes?
Evaluation of ANAVEX2-73 (blarcamesine) in Participants with Parkinson’s Disease
Market Data 
Markets 
AI
